- Home
- DTST vs ENVB Comparison
DTST vs ENVB Comparison
Compare DTST & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTST | ENVB |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.7M |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DTST | ENVB |
|---|---|---|
| Price | $3.00 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.1K | ★ 59.7K |
| Earning Date | 11-18-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3671.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,382,929.00 | ★ $39,914,675.00 |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.75 | $1.17 |
| 52 Week High | $5.15 | $795.00 |
Technical Indicators
Market Signals| Indicator | DTST | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 54.21 |
| Support Level | $2.82 | $1.37 |
| Resistance Level | $3.15 | $1.53 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 17.53 | 65.84 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc and corporate segment. It generates maximum revenue from the Nexxis Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.